CL2012000461A1 - Compuestos derivados de piridina fusionada con otro heterociclo, inhibidores del smo; composicion farmaceutica; y uso para la profilaxis o tratamiento del cancer. - Google Patents

Compuestos derivados de piridina fusionada con otro heterociclo, inhibidores del smo; composicion farmaceutica; y uso para la profilaxis o tratamiento del cancer.

Info

Publication number
CL2012000461A1
CL2012000461A1 CL2012000461A CL2012000461A CL2012000461A1 CL 2012000461 A1 CL2012000461 A1 CL 2012000461A1 CL 2012000461 A CL2012000461 A CL 2012000461A CL 2012000461 A CL2012000461 A CL 2012000461A CL 2012000461 A1 CL2012000461 A1 CL 2012000461A1
Authority
CL
Chile
Prior art keywords
prophylaxis
cancer
treatment
pharmaceutical composition
compounds derived
Prior art date
Application number
CL2012000461A
Other languages
English (en)
Spanish (es)
Inventor
Satoshi Tanaka Yuta Sasaki
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43627972&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012000461(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of CL2012000461A1 publication Critical patent/CL2012000461A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CL2012000461A 2009-08-26 2012-02-23 Compuestos derivados de piridina fusionada con otro heterociclo, inhibidores del smo; composicion farmaceutica; y uso para la profilaxis o tratamiento del cancer. CL2012000461A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009195770 2009-08-26
JP2010015644 2010-01-27

Publications (1)

Publication Number Publication Date
CL2012000461A1 true CL2012000461A1 (es) 2012-10-05

Family

ID=43627972

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012000461A CL2012000461A1 (es) 2009-08-26 2012-02-23 Compuestos derivados de piridina fusionada con otro heterociclo, inhibidores del smo; composicion farmaceutica; y uso para la profilaxis o tratamiento del cancer.

Country Status (24)

Country Link
US (1) US8907089B2 (enExample)
EP (1) EP2471790B1 (enExample)
JP (1) JP5599802B2 (enExample)
KR (1) KR20120078703A (enExample)
CN (1) CN102574851A (enExample)
AU (1) AU2010287492A1 (enExample)
BR (1) BR112012004134A2 (enExample)
CA (1) CA2771833A1 (enExample)
CL (1) CL2012000461A1 (enExample)
CR (1) CR20120095A (enExample)
DO (1) DOP2012000048A (enExample)
EA (1) EA201270311A1 (enExample)
EC (1) ECSP12011747A (enExample)
GE (1) GEP20146075B (enExample)
IL (1) IL218323A0 (enExample)
IN (1) IN2012DN02069A (enExample)
MA (1) MA33589B1 (enExample)
MX (1) MX2012002419A (enExample)
NZ (1) NZ598749A (enExample)
PE (1) PE20121326A1 (enExample)
SG (1) SG178504A1 (enExample)
TN (1) TN2012000084A1 (enExample)
WO (1) WO2011024872A1 (enExample)
ZA (1) ZA201201795B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2471793B1 (en) * 2009-08-26 2016-10-05 Takeda Pharmaceutical Company Limited Fused heterocyclic ring derivative and use thereof
US9670221B2 (en) 2013-03-14 2017-06-06 Glaxosmithkline Intellectual Property (No. 2) Limited Furopyridines as bromodomain inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6436965B1 (en) 2000-03-02 2002-08-20 Merck Frosst Canada & Co. PDE IV inhibiting amides, compositions and methods of treatment
WO2002012189A1 (en) 2000-08-09 2002-02-14 Mitsubishi Pharma Corporation Fused bicyclic amide compounds and medicinal use thereof
US7998986B2 (en) 2001-12-21 2011-08-16 Exelixis Patent Company Llc Modulators of LXR
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
AU2003265853A1 (en) 2002-08-29 2004-03-19 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
WO2005033288A2 (en) * 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
WO2005081960A2 (en) 2004-02-25 2005-09-09 Wyeth Inhibitors of protein tyrosine phosphatase 1b
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US8273747B2 (en) 2006-11-02 2012-09-25 Curis, Inc. Small organic molecule regulators of cell proliferation
WO2008057469A1 (en) * 2006-11-02 2008-05-15 Wyeth Small organic molecule regulators of cell proliferation
CA2690953C (en) 2007-06-29 2012-10-02 Pfizer Inc. Benzimidazole derivatives
RU2364597C1 (ru) * 2007-12-14 2009-08-20 Андрей Александрович Иващенко ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ Hh-СИГНАЛЬНОГО КАСКАДА, ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АББЕРАНТНОЙ АКТИВНОСТЬЮ Hh СИГНАЛЬНОЙ СИСТЕМЫ
JP4685891B2 (ja) 2008-02-19 2011-05-18 株式会社ハネックス 分離装置
CN102015705B (zh) * 2008-02-26 2013-11-13 武田药品工业株式会社 稠合的杂环衍生物及其用途
JP2010015644A (ja) 2008-07-04 2010-01-21 Fujitsu Ltd スピンドル機構、電磁変換特性評価機、および情報記憶装置
GB0900484D0 (en) 2009-01-13 2009-02-11 Angeletti P Ist Richerche Bio Therapeutic agent

Also Published As

Publication number Publication date
EA201270311A1 (ru) 2012-09-28
SG178504A1 (en) 2012-04-27
IL218323A0 (en) 2012-04-30
WO2011024872A1 (ja) 2011-03-03
TN2012000084A1 (en) 2013-09-19
MA33589B1 (fr) 2012-09-01
US8907089B2 (en) 2014-12-09
ZA201201795B (en) 2013-05-29
BR112012004134A2 (pt) 2017-06-20
EP2471790A1 (en) 2012-07-04
PE20121326A1 (es) 2012-10-11
AU2010287492A1 (en) 2012-03-29
DOP2012000048A (es) 2012-05-15
MX2012002419A (es) 2012-04-19
US20120220570A1 (en) 2012-08-30
NZ598749A (en) 2013-01-25
JP5599802B2 (ja) 2014-10-01
JPWO2011024872A1 (ja) 2013-01-31
EP2471790B1 (en) 2015-03-18
ECSP12011747A (es) 2012-05-30
IN2012DN02069A (enExample) 2015-08-21
CR20120095A (es) 2012-06-26
CA2771833A1 (en) 2011-03-03
EP2471790A4 (en) 2013-07-31
CN102574851A (zh) 2012-07-11
GEP20146075B (en) 2014-04-10
KR20120078703A (ko) 2012-07-10

Similar Documents

Publication Publication Date Title
CL2015002194A1 (es) Inhbidores de erk y sus usos
CL2015002932A1 (es) Inhibidores de proteína quinasa
CL2012002250A1 (es) Compuestos heterociclicos fusionados derivados de pirimidinonas, inhibidores potentes de cdc7; composicion farmaceutica; y su uso en la prevencion o el tratamiento del cancer.
CL2011000454A1 (es) Compuestos derivados de picolinamida, inhibidores de quinasa pim, asociada a tumorigenesis; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
CL2015002658A1 (es) Derivados de 2, 3 - disustituto 1- acil -4 amino - 1,2,3,4 tetrahidroquinilina y su uso como inhibidores de bromodominio
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
CL2012002189A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos.
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
CL2009000483A1 (es) Compuestos derivados de n-(piridin-3-il)-1,3-tiazol-5-amino-4-carboxamida, inhibidores de cinasa pim; composicion farmaceutica; y uso para el tratamiento del cancer.
CL2012001422A1 (es) Compuestos derivados de sulfonil benzamidas sustituidas, inductores de apoptosis con selectividad por bcl-2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
CL2015003442A1 (es) Derivados heterociclicos
CL2011000691A1 (es) Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
MX2016002137A (es) Ciertas entidades quimicas, composiciones y metodos.
MX2016012097A (es) Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cáncer.
CL2015002472A1 (es) Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4.
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
CL2016000922A1 (es) Derivados de anillo bicíclico fusionado piridilo como inhibidores fgfr4
MX2016008131A (es) Compuestos heterociclos biciclicos y sus usos en terapia.
CL2008002097A1 (es) Compuestos derivados de heterociclos condensados sustituidos, inhibidores de cinasa de fosfatidil-inositol-3; composicion farmaceutica; y uso en el tratamiento del cancer.
NI201100166A (es) Derivados de benzofuranilo utilizados como inhibidores de glucoquinasa
EA201591509A1 (ru) Ингибиторы cdc7
CL2015003315A1 (es) Inhibidores de acc y usos de los mismos
UY35485A (es) Compuestos heterocíclicos y usos de los mismos